[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100321333":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":18,"centralContacts":18,"locations":19,"responsibleParty":31,"collaborators":18,"id":35,"slug":36,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":39,"acronym":18,"eligibilityCriteria":40,"healthyVolunteers":37,"sex":41,"minAge":42,"maxAge":18,"enrollmentInfo":43,"targetDuration":18,"studyType":46,"phases":47,"briefSummary":49,"conditions":50,"keywords":18,"overallStatus":52,"whyStopped":18,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":61},{"fullName":5,"class":6},"Samsung Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Hyaluronic Acid and Chondroitin Sulfate","EXPERIMENTAL","Intravesical instillation of Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis\u002FBladder Pain Syndrome Patients.",[13],"Drug: Hyaluronic Acid and Chondroitin Sulfate",[15],{"type":16,"name":9,"description":11,"armGroupLabels":17,"otherNames":18},"DRUG",[9],null,[20],{"facility":21,"status":18,"city":22,"state":18,"zip":23,"country":24,"countryCode":18,"cosmosGeoPoint":25,"geoPoint":30,"contacts":18},"Samsung Medical Center, Sungkyunkwan University School of Medicine","Seoul","135-710","South Korea",{"type":26,"coordinates":27},"Point",[28,29],126.9784,37.566,{"lat":29,"lon":28},{"type":32,"investigatorFullName":33,"investigatorTitle":34,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","KYU-SUNG LEE","professor","100321333","the-efficacy-and-safety-of-intravesical-hyaluronic-acid-and-chondroitin-sulfate-after-transurethral-resection-of-hunner-lesion-in-interstitial-cystitisbladder-pain-syndrome-patients-100321333",false,"NCT03463499","The Efficacy and Safety of Intravesical Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis\u002FBladder Pain Syndrome Patients","Inclusion Criteria:\n\n1. Male and female aged 20 yrs or greater\n2. Patients diagnosed with Hunner lesion in IC(interstitial cystitis)\u002FBPS(Bladder Pain Syndrome) and who is scheduled to undergo transurethral resection\n3. Symptom persisted more than 6 months\n4. Pain VAS ≥4\n\nExclusion Criteria:\n\n1. History of augmentation cystoplasty or previous transurethral coagulation\u002Fresection due to IC\u002FBPS\n2. Child-bearing potential, pregnant or nursing women.\n3. Hematuria exceeds 1+ in the urinary dipstick (dipstick) examination.\n4. Urinary tract infection during run-in periods.\n5. Genitourinary tuberculosis or bladder,urethral and prostate cancer\n6. Recurrent urinary tract infection\n7. History of hysterectomy,mid-urethral sling,pelvic organ prolapse repair,vaginal delivery or Cesarean section,prostate operation or treatment etc within 6months.\n8. Neurologic disease history of cerebral infarction,multiple sclerosis or parkinsonism etc.-\n9. Using a indwelling catheter or execution of intermittent self catheterization","ALL","20 Years",{"count":44,"type":45},62,"ACTUAL","INTERVENTIONAL",[48],"NA","The efficacy and safety of intravesical hyaluronic acid and chondroitin sulfate after transurethral resection of Hunner lesion in interstitial cystitis\u002Fbladder pain syndrome patients. To analyze the number and timing of recurrence based on a long-term follow-up.",[51],"Interstitial Cystitis","COMPLETED","2022-10-26",{"date":55,"type":45},"2022-10-27",{"date":57,"type":45},"2017-09-22",{"date":59,"type":45},"2021-12-31",{"name":5,"class":6},1]